+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Factor VIII"

Human Factor VIII Concentrate Market - Global Forecast 2026-2032 - Product Thumbnail Image

Human Factor VIII Concentrate Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 199 Pages
  • Global
From
Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026 - Product Thumbnail Image

Hemophilia A (Factor VIII Deficiency) - Global Clinical Trials Review, 2026

  • Clinical Trials
  • March 2026
  • 501 Pages
  • Global
From
From
Hemophilia Treatment Market - Global Forecast 2026-2032 - Product Thumbnail Image

Hemophilia Treatment Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 184 Pages
  • Global
From
Von Willebrand Disease Treatment Market - Global Forecast 2026-2032 - Product Thumbnail Image

Von Willebrand Disease Treatment Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 187 Pages
  • Global
From
From
Emicizumab Injection Market - Global Forecast 2026-2032 - Product Thumbnail Image

Emicizumab Injection Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 193 Pages
  • Global
From
Recombinant Coagulation Factors - Global Strategic Business Report - Product Thumbnail Image

Recombinant Coagulation Factors - Global Strategic Business Report

  • Report
  • September 2026
  • 377 Pages
  • Global
From
Hemophilia Drugs - Global Strategic Business Report - Product Thumbnail Image

Hemophilia Drugs - Global Strategic Business Report

  • Report
  • September 2026
  • 196 Pages
  • Global
From
Coagulation Factor Concentrates - Global Strategic Business Report - Product Thumbnail Image

Coagulation Factor Concentrates - Global Strategic Business Report

  • Report
  • September 2026
  • 254 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Loading Indicator

The Factor VIII market is a segment of the hematological drugs market, which includes drugs used to treat blood-related disorders. Factor VIII is a protein that helps blood to clot, and is used to treat hemophilia A, a genetic disorder that impairs the body's ability to form blood clots. Factor VIII is typically administered intravenously, and is available in both recombinant and plasma-derived forms. The Factor VIII market is highly competitive, with a number of companies offering products. These include Novo Nordisk, Pfizer, Bayer, CSL Behring, and Shire. Additionally, there are several smaller companies that offer Factor VIII products, such as Octapharma, Kedrion, and Biotest. Show Less Read more